153 related articles for article (PubMed ID: 34486071)
21. Iodinated benzimidazole PARP radiotracer for evaluating PARP1/2 expression in vitro and in vivo.
Anderson RC; Makvandi M; Xu K; Lieberman BP; Zeng C; Pryma DA; Mach RH
Nucl Med Biol; 2016 Dec; 43(12):752-758. PubMed ID: 27689533
[TBL] [Abstract][Full Text] [Related]
22. Dual-Modality Optical/PET Imaging of PARP1 in Glioblastoma.
Carlucci G; Carney B; Brand C; Kossatz S; Irwin CP; Carlin SD; Keliher EJ; Weber W; Reiner T
Mol Imaging Biol; 2015 Dec; 17(6):848-55. PubMed ID: 25895168
[TBL] [Abstract][Full Text] [Related]
23. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
24. Kinetic and Static Analysis of Poly-(Adenosine Diphosphate-Ribose) Polymerase-1-Targeted
Young AJ; Pantel AR; Viswanath V; Dominguez TL; Makvandi M; Lee H; Li S; Schubert EK; Pryma DA; Farwell MD; Mach RH; Simpkins F; Lin LL; Mankoff DA; Doot RK
J Nucl Med; 2022 Jan; 63(1):44-50. PubMed ID: 33863820
[TBL] [Abstract][Full Text] [Related]
25. N
Fukumoto T; Zhu H; Nacarelli T; Karakashev S; Fatkhutdinov N; Wu S; Liu P; Kossenkov AV; Showe LC; Jean S; Zhang L; Zhang R
Cancer Res; 2019 Jun; 79(11):2812-2820. PubMed ID: 30967398
[TBL] [Abstract][Full Text] [Related]
26. The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.
Marzio A; Puccini J; Kwon Y; Maverakis NK; Arbini A; Sung P; Bar-Sagi D; Pagano M
Mol Cell; 2019 Jan; 73(2):224-237.e6. PubMed ID: 30554948
[TBL] [Abstract][Full Text] [Related]
27. PARP targeted Auger emitter therapy with [
Ambur Sankaranarayanan R; Florea A; Allekotte S; Vogg ATJ; Maurer J; Schäfer L; Bolm C; Terhorst S; Classen A; Bauwens M; Morgenroth A; Mottaghy FM
EJNMMI Res; 2022 Sep; 12(1):60. PubMed ID: 36104637
[TBL] [Abstract][Full Text] [Related]
28. Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma.
Vormoor B; Curtin NJ
Curr Opin Oncol; 2014 Jul; 26(4):428-33. PubMed ID: 24840521
[TBL] [Abstract][Full Text] [Related]
29. Preclinical and first-in-human-brain-cancer applications of [
Young RJ; Demétrio De Souza França P; Pirovano G; Piotrowski AF; Nicklin PJ; Riedl CC; Schwartz J; Bale TA; Donabedian PL; Kossatz S; Burnazi EM; Roberts S; Lyashchenko SK; Miller AM; Moss NS; Fiasconaro M; Zhang Z; Mauguen A; Reiner T; Dunphy MP
Neurooncol Adv; 2020; 2(1):vdaa119. PubMed ID: 33392502
[TBL] [Abstract][Full Text] [Related]
30. PARP-1 Expression Quantified by [
Sander Effron S; Makvandi M; Lin L; Xu K; Li S; Lee H; Hou C; Pryma DA; Koch C; Mach RH
Cancer Biother Radiopharm; 2017 Feb; 32(1):9-15. PubMed ID: 28118040
[TBL] [Abstract][Full Text] [Related]
31. EGFR and c-MET Cooperate to Enhance Resistance to PARP Inhibitors in Hepatocellular Carcinoma.
Dong Q; Du Y; Li H; Liu C; Wei Y; Chen MK; Zhao X; Chu YY; Qiu Y; Qin L; Yamaguchi H; Hung MC
Cancer Res; 2019 Feb; 79(4):819-829. PubMed ID: 30573522
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of [
Jiang H; Zhang R; Jiang H; Zhang M; Guo W; Feng G; Pan W; Xu H; Wang S
Nucl Med Biol; 2019; 72-73():36-44. PubMed ID: 31330410
[TBL] [Abstract][Full Text] [Related]
33. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
[No Abstract] [Full Text] [Related]
34. Trastuzumab-Resistant HER2
Wielgos ME; Zhang Z; Rajbhandari R; Cooper TS; Zeng L; Forero A; Esteva FJ; Osborne CK; Schiff R; LoBuglio AF; Nozell SE; Yang ES
Mol Cancer Ther; 2018 May; 17(5):921-930. PubMed ID: 29592880
[TBL] [Abstract][Full Text] [Related]
35. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.
Clark CC; Weitzel JN; O'Connor TR
Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154
[TBL] [Abstract][Full Text] [Related]
36. RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance.
Wang Y; Krais JJ; Bernhardy AJ; Nicolas E; Cai KQ; Harrell MI; Kim HH; George E; Swisher EM; Simpkins F; Johnson N
J Clin Invest; 2016 Aug; 126(8):3145-57. PubMed ID: 27454289
[TBL] [Abstract][Full Text] [Related]
37. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
Jiao S; Xia W; Yamaguchi H; Wei Y; Chen MK; Hsu JM; Hsu JL; Yu WH; Du Y; Lee HH; Li CW; Chou CK; Lim SO; Chang SS; Litton J; Arun B; Hortobagyi GN; Hung MC
Clin Cancer Res; 2017 Jul; 23(14):3711-3720. PubMed ID: 28167507
[No Abstract] [Full Text] [Related]
38. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.
Tentori L; Ricci-Vitiani L; Muzi A; Ciccarone F; Pelacchi F; Calabrese R; Runci D; Pallini R; Caiafa P; Graziani G
BMC Cancer; 2014 Mar; 14():151. PubMed ID: 24593254
[TBL] [Abstract][Full Text] [Related]
39. Comparisons of [18F]-1-deoxy-1-fluoro-scyllo-inositol with [18F]-FDG for PET imaging of inflammation, breast and brain cancer xenografts in athymic mice.
McLarty K; Moran MD; Scollard DA; Chan C; Sabha N; Mukherjee J; Guha A; McLaurin J; Nitz M; Houle S; Wilson AA; Reilly RM; Vasdev N
Nucl Med Biol; 2011 Oct; 38(7):953-9. PubMed ID: 21982567
[TBL] [Abstract][Full Text] [Related]
40. MEK Inhibition Remodels the Immune Landscape of Mutant
Yang B; Li X; Fu Y; Guo E; Ye Y; Li F; Liu S; Xiao R; Liu C; Lu F; Huang J; Qin T; Han L; Peng G; Mills GB; Sun C; Chen G
Cancer Res; 2021 May; 81(10):2714-2729. PubMed ID: 33589518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
